The AUA puts two big men's health topics side by side and asks whether GLP-1 medications might do more than help with weight loss.
Recap by typeshit. Post by Amer. Urol. Assn. on X.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
In 367 adults with type 2 diabetes, the top combo dose beat 14.8% on tirzepatide alone at 48 weeks. Lilly plans phase 3 by late 2026.
A new paper presents a computational pipeline for designing peptide binders, aiming to fix cases where deep learning confidence scores mislead.
Loading…